1. IDENTIFICATION OF THE SUBSTANCE AND THE COMPANY

Material Tramadol Hydrochloride Extended-Release Tablets 100 mg, 200 mg & 300 mg
Manufacturer Lupin Limited
Pithampur (M.P) - 454775
INDIA
Distributor Lupin Pharmaceuticals, Inc.
Harborplace Tower, 21st Floor
111, South Calvert Street
Baltimore, MD 21202
United States
Tel. 001-410-576-2000
Fax 001-410-576-2221

2. COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>CAS</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tramadol Hydrochloride</td>
<td>36282-47-0</td>
<td>100 mg, 200 mg &amp; 300 mg</td>
</tr>
<tr>
<td>Non-hazardous ingredients</td>
<td>----------</td>
<td>q.s.</td>
</tr>
</tbody>
</table>

3. HAZARDOUS IDENTIFICATION

Fire and Explosion
Assume that this product is capable of sustaining combustion.

Health
Tramadol hydrochloride extended-release tablet should not be administered to patients who have previously demonstrated hypersensitivity to tramadol, any other component of this product or opioids. Tramadol hydrochloride extended-release tablet is contraindicated in any situation where opioids are contraindicated, including acute intoxication with any of the following: alcohol, hypnotics, and narcotics, centrally acting analgesics, opioids or psychotropic drugs. Tramadol hydrochloride extended-release tablet may worsen central nervous system and respiratory depression in these patients.

Environment
No information is available about the potential of this product to produce adverse environmental effects.
4. FIRST AID MEASURES

Ingestion
If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

Inhalation
Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

Skin Contact
Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

Eye Contact
Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

Acute overdosage with tramadol can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, bradycardia, hypotension, and death.

Deaths due to overdose have been reported with abuse and misuse of tramadol, by ingesting, inhaling, or injecting the crushed tablets. Review of case reports has indicated that the risk of fatal overdose is further increased when tramadol is abused concurrently with alcohol or other CNS depressants, including other opioids.

In the treatment of tramadol overdose, primary attention should be given to the re-establishment of a patent airway and institution of assisted or controlled ventilation. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation.

While naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, the risk of seizures is also increased with naloxone administration. In animals convulsions following the administration of toxic doses of tramadol hydrochloride extended release tablet could be suppressed with barbiturates or benzodiazepines but were increased with naloxone. Naloxone administration did not change the lethality of an overdose in mice. Hemodialysis is not expected to be helpful in an overdose because it removes less than 7% of the administered dose in a 4-hour dialysis period.
5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards
Assume that this product is capable of sustaining combustion.

Extinguishing Media
Water spray, carbon dioxide, dry chemical powder or appropriate foam.

Special Firefighting Procedures
For single units (packages): No special requirements needed.

Hazardous Combustion Products
Hazardous combustion or decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions
Wear protective clothing and equipment consistent with the degree of hazard.

Environmental Precautions
For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Clean-up Methods
Collect and place it in a suitable, properly labeled container for recovery or disposal.

7. HANDLING AND STORAGE

Handling
No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.

Storage
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature].

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.
9. PHYSICAL & CHEMICAL PROPERTIES

Physical Form

Tramadol Hydrochloride Extended-Release Tablets are supplied in the following package and dose strength forms:

100 mg: White to off-white circular, biconvex, beveled edge coated tablets imprinted with ‘L010’ on one side and plain on the other side.

Bottles of 30 tablets : NDC 68180-383-06
Bottles of 100 tablets : NDC 68180-383-01
Bottles of 500 tablets : NDC 68180-383-02

200 mg: White to off-white circular, biconvex, beveled edge coated tablets imprinted with ‘L011’ on one side and plain on the other side.

Bottles of 30 tablets : NDC 68180-384-06
Bottles of 100 tablets : NDC 68180-384-01
Bottles of 500 tablets : NDC 68180-384-02

300 mg: White to off-white circular, biconvex, beveled edge coated tablets imprinted with ‘L012’ on one side and plain on the other side.

Bottles of 30 tablets : NDC 68180-385-06
Bottles of 100 tablets : NDC 68180-385-01

10. STABILITY AND REACTIVITY

Stable under recommended storage conditions.

11. TOXICOLOGICAL INFORMATION

Carcinogenesis, Mutagenesis, Impairment of Fertility:

No carcinogenic effect of tramadol was observed in p53 (+/−)-heterozygous mice at oral doses up to 150 mg/kg/day (approximately 2-fold maximum daily human dose [MDHD] of 400 mg/day for a 60 kg adult based on body surface conversion) for 26 weeks and in rats at oral doses up to 75 mg/kg/day for males and 100 mg/kg/day for females (approximately 2-fold MDHD) for two years. However, the excessive decrease in body weight gain observed in the rat study might have reduced their sensitivity to any potential carcinogenic effect of the drug.

Tramadol was not mutagenic in the following assays: a bacterial reverse mutation assay using Salmonella and E. coli, a mouse lymphoma assay (in the absence of metabolic activation), and a bone marrow micronucleus test in mice. Mutagenic results occurred in the...
12. ECOLOGICAL INFORMATION

No relevant studies identified.

13. DISPOSAL CONSIDERATION

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

14. TRANSPORT INFORMATION

The Material Safety Data Sheet (MSDS) should accompany all shipments for reference in the event of spillage or accidental release. Transportation and shipping of this product is not restricted. It has no known, significant hazards requiring special packaging or labeling for air, maritime, or ground transport purposes.

15. REGULATORY INFORMATION

No information found.

16. OTHER INFORMATION

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.